FindMyKOL
Clinical trialNCT01616303CompletedPhase 2Interventional

A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer

NCT01616303 is a phase 2 interventional trial sponsored by Quest PharmaTech Inc.. As of 21 Nov 2026, it is completed. It studies Carboplatin, Paclitaxel and Oregovomab in Ovarian Neoplasms. The registry lists an enrollment of 97 participants at 2 sites in 1 country. The registry lists a start date of 15 Jun 2012 and a primary completion date of 15 Jun 2015.

SponsorQuest PharmaTech Inc.Enrollment97Ovarian Neoplasms
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT01616303
FieldValue
Registry IDNCT01616303
StatusCompleted
PhasePhase 2
Study typeInterventional trial
Lead sponsorQuest PharmaTech Inc.
Enrollment97
Registered sites2
Countries1
ConditionsOvarian Neoplasms
DrugsCarboplatin, Paclitaxel and Oregovomab
Start15 Jun 2012
Primary completion15 Jun 2015
Study completion12 Oct 2018
Last update posted14 Sept 2020
Other registry IDsEU-CTR / CTIS (EudraCT) 2010-024305-13

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 2 randomized study with two treatment arms to compare the effectiveness of oregovomab (a murine monoclonal antibody directed against cancer antigen 125 (CA125)) when combined with first-line chemotherapy (carboplatin and paclitaxel) to first-line chemotherapy (carboplatin and paclitaxel alone) in female patients with advanced ovarian cancer.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Connecticut, United States1 site
  • University of Connecticut Health Center

    Farmington

Indiana, United States1 site
  • Northern Indiana Cancer Research Consortium

    South Bend

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndiana: 1 siteIN1OhioOHPennsylvaniaPANew JerseyNJConnecticut: 1 siteCT1CaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT01616303

Each answer restates registry values shown on this page.

What is NCT01616303?

NCT01616303 is a phase 2 interventional trial sponsored by Quest PharmaTech Inc.. It studies Carboplatin, Paclitaxel and Oregovomab in Ovarian Neoplasms.

Who leads NCT01616303?

The registry names Christopher Nicodemus, MD FACP (study chair, AIT Strategies) and Thomas Woo, M.Sc. (study director, Quest PharmaTech Inc.) as overall officials.

Where does NCT01616303 run?

The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT01616303 study?

The registered drug and biological interventions are Carboplatin, Paclitaxel and Oregovomab.

When did NCT01616303 end?

The registry lists a primary completion date of 15 Jun 2015 and a study completion date of 12 Oct 2018. The sponsor last updated the record on 14 Sept 2020.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.